Dominari (NASDAQ:DOMH) Rating Lowered to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Dominari from “hold” to “sell,” while Weiss Ratings reaffirmed its “sell (D-)” rating. The stock’s consensus rating is currently “Sell.”
• Dominari shares opened at $2.71, near the lower end of their 52-week range of $2.19 to $8.40, with a market capitalization of approximately $65.7 million.
• The company reported a quarterly loss of $0.21 per share, better than the expected $0.34 loss, and revenue of $16.79 million. However, it continues to show significant financial weakness, including a negative 235.37% return on equity and a negative 51.61% net margin.

Dominari (NASDAQ:DOMH - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dominari in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Sell".

Dominari Price Performance

Shares of NASDAQ:DOMH opened at $2.71 on Friday. The stock has a market capitalization of $65.69 million, a P/E ratio of -0.50 and a beta of 0.87. The business has a 50-day moving average of $2.88 and a two-hundred day moving average of $3.12. Dominari has a fifty-two week low of $2.19 and a fifty-two week high of $8.40.

Dominari (NASDAQ:DOMH - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.13. Dominari had a negative return on equity of 235.37% and a negative net margin of 51.61%.The business had revenue of $16.79 million for the quarter, compared to analyst estimates of $16.79 million.

Institutional Investors Weigh In On Dominari

Several hedge funds and other institutional investors have recently made changes to their positions in DOMH. Renaissance Technologies LLC lifted its position in shares of Dominari by 59.1% during the 1st quarter. Renaissance Technologies LLC now owns 132,362 shares of the company's stock worth $430,000 after purchasing an additional 49,162 shares during the last quarter. PFG Investments LLC boosted its stake in Dominari by 36.3% during the 1st quarter. PFG Investments LLC now owns 14,475 shares of the company's stock valued at $47,000 after purchasing an additional 3,855 shares during the period. Creek Drive Management Group LLC acquired a new stake in Dominari in the 4th quarter valued at approximately $1,861,000. NewEdge Advisors LLC acquired a new stake in Dominari in the 4th quarter valued at approximately $50,000. Finally, Oxford Asset Management LLP bought a new position in Dominari in the 4th quarter worth approximately $120,000. 42.48% of the stock is owned by institutional investors and hedge funds.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source